Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | FGFR3 S249C |
| Therapy | Fexagratinib |
| Indication/Tumor Type | renal pelvis transitional cell carcinoma |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| FGFR3 S249C | renal pelvis transitional cell carcinoma | predicted - sensitive | Fexagratinib | Case Reports/Case Series | Actionable | In a Phase II (MATCH) trial, Fexagratinib (AZD4547) treatment resulted in an overall response rate of 10.5% (2/19) in patients with advanced solid tumors harboring FGFR2 or 3 activating single nucleotide variants and a 6-month progression-free survival rate of 6%, including stable disease for greater than 6 months in a patient with transitional cell carcinoma of the renal pelvis harboring FGFR3 S249C (PMID: 32463741; NCT02465060). | 32463741 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (32463741) | Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W. | Full reference... |